ArticleDiscover oncology2026
CDC42SE1 as a novel prognostic biomarker with immunomodulatory associations in breast invasive carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to investigate the expression pattern, prognostic significance, and immune-related role of CDC42SE1 in breast invasive carcinoma (BRCA).
methodsRNA sequencing and clinical data from TCGA-BRCA and GEO datasets (GSE42568, GSE10810) were analyzed. CDC42SE1 expression was compared between tumor and normal tissues. Survival analyses, univariate and multivariate Cox regression, immune infiltration estimation (ssGSEA), and functional enrichment analyses were performed. A nomogram was constructed to predict patient survival.
resultsCDC42SE1 was significantly upregulated in BRCA tissues compared to normal controls (p < 0.001; AUC = 0.757), with validation in two independent GEO cohorts and at the protein level (CPTAC). High CDC42SE1 expression correlated with reduced overall survival (p = 0.014; HR = 1.43) and was identified as an independent prognostic factor in multivariate analysis (HR = 1.43, p = 0.033). Immune infiltration analysis revealed moderate positive associations with Tcm (R = 0.335), Th2, and Th17 cells, and negative associations with pDCs and cytotoxic cells. Functional enrichment linked CDC42SE1 to histone modification, ubiquitin-mediated proteolysis, and mRNA surveillance pathways. A nomogram incorporating CDC42SE1 showed moderate accuracy in predicting 1-, 3-, and 5-year survival (AUC: 0.580–0.585).
conclusionCDC42SE1 is overexpressed in BRCA and associated with poor prognosis and altered immune infiltration, suggesting its potential as a prognostic biomarker with immunomodulatory relevance. Further mechanistic studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.